Celyad Oncology S.A.
CYAD
Classifica tra le azioni
#31769
Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to... Celyad Oncology S.A. is a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing chimeric antigen receptor T (CAR-T) cell therapies specifically for oncology. Its most advanced therapeutic programs include several candidates undergoing clinical trials. CYAD-101 is an allogeneic CAR-T treatment currently in a Phase 1b study targeting metastatic colorectal cancer. Another allogeneic candidate, CYAD-211, utilizes short hairpin RNA (shRNA) technology and is being evaluated in a Phase 1 trial for patients with relapsed or refractory multiple myeloma. Furthermore, CYAD-02, an autologous CAR-T therapy, is progressing through a Phase 1 study to address relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. In its preclinical pipeline, the company is developing CYAD-203. This is a non-gene-edited allogeneic CAR-T candidate designed to co-express interleukin-18 (IL-18) cytokine with natural killer group 2D ligands (NKG2D), intended for the treatment of various solid tumors. Celyad Oncology holds a licensing agreement with Novartis International AG, granting rights to U.S. patents concerning allogeneic CAR-T cells. Additionally, it has established research and development collaborations and licensing agreements with Horizon Discovery Group plc, leveraging their shRNA technology to create an alternative non-gene-edited allogeneic platform. Established in 2004, the company was initially known as Celyad SA before rebranding to Celyad Oncology SA in June 2020. Its headquarters are situated in Mont-Saint-Guibert, Belgium.
Prezzo delle azioni
$0.24434797
Capitalizzazione di mercato
$11.55M
Variazione (1 giorno)
-9.25%
Variazione (1 anno)
-48.01%
Paese
BE
Scambia Celyad Oncology S.A. (CYAD)
Categoria
Healthcare
Storico dividendi per Celyad Oncology S.A. (CYAD)
Celyad Oncology S.A. (simbolo azionario: CYAD) ha effettuato un totale di 0 pagamenti di dividendi.
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
La somma totale dei dividendi (rettificata per split azionari) è: 0.00
Rendimento da dividendo (TTM): 0
Pagamenti dei dividendi per Celyad Oncology S.A. (CYAD) dal 2026 al 2026
Pagamenti annuali dei dividendi
| Anno | Dividendo (rettificato per split azionari) | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
Elenco di tutti i pagamenti di dividendi
| Anno | Dividendo | Cambia |
|---|---|---|
| Non abbastanza dati per le date fornite. | ||
Dividendi di aziende simili o concorrenti
| Azienda | Numero di pagamenti di dividendi | Il paese |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
